Insulet (PODD) AI Stock Analysis

• Market Cap: $16.62B
• Dividend Yield: N/A
• Average Volume (3M): 1.10M
• Price to Earnings (P/E): 80.9
• Beta (1Y): 0.70
• Revenue Growth: 27.12%
• EPS Growth: -41.72%
• Country: US
• Employees: 3,900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.55
• Shares Outstanding: 70,395,850
• 10 Day Avg. Volume: 994,495
• 30 Day Avg. Volume: 1,095,949
• PEG Ratio: -1.96
• Price to Book (P/B): 13.20
• Price to Sales (P/S): 7.38
• P/FCF Ratio: 52.94
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 6.26
• Enterprise Value/Gross Profit: 8.74
• Enterprise Value/Ebitda: 34.84
• 1Y Price Target: $353.45
• Price Target Upside: 49.72% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 21
• EPS Forecast (FY): 6.34
• Revenue Forecast (FY): $3.31B

• Rating: 68 Neutral
• Price Target: $260.00 ▲(10.14% Upside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is driven primarily by strong financial performance (high margins, improved cash generation, and a much less levered 2025 balance sheet) and a constructive earnings outlook with continued growth, margin expansion, and buybacks. These positives are tempered by weak technicals (price below key moving averages with negative MACD) and a premium valuation (P/E ~81) that leaves less room for execution missteps amid guidance deceleration and higher capex/interest headwinds.

Positive Factors

Recurring revenue & installed-base growth

Conversion of MDI users and strong type‑2 adoption broaden the Omnipod installed base, reinforcing a razor/razorblade revenue stream of repeat Pod purchases. Durable installed‑base growth improves revenue visibility, retention economics and lifecycle monetization over multi‑year horizons.

High and expanding product margins

Sustained ~72% gross margins and expanding operating margins reflect pricing power, favorable product mix (Omnipod 5/DASH conversions) and manufacturing scale. High structural margins provide durable capacity to fund R&D, commercial expansion and cushion against reimbursement headwinds over the medium term.

Stronger cash generation and de‑risked balance sheet

Positive FCF near $378M and a materially de‑levered balance sheet grant financial flexibility to fund capex, manufacturing scale, M&A or buybacks. Improved cash conversion and low net debt increase resilience to operational shocks and support multi‑year investment plans and capital allocation execution.

Negative Factors

Manufacturing quality risk

A manufacturing defect and device correction introduce regulatory and reputational risk that can persist beyond the immediate recall. Even if limited, remediation costs (up to ~$40M disclosed) and heightened scrutiny can increase ongoing QA costs, slow new patient starts and require sustained CAPEX and process controls.

Ramping capital intensity

Material capex ramp to expand manufacturing and automation raises near‑term capital intensity and reduces free cash flow flexibility. Combined with higher interest expense from refinancing and large planned buybacks, this constrains liquidity buffers and increases reliance on execution to realize margin and volume benefits.

Earnings volatility and reporting inconsistency

Substantial year‑over‑year net margin swing and an EBIT margin inconsistency reduce confidence in trend extrapolation. Coupled with a decline in FCF versus 2024 and one‑time tax benefits, margin volatility complicates forecasting and raises execution risk for sustaining current profitability levels.

Insulet Business Overview & Revenue Model

Company Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

How the Company Makes Money

Insulet primarily makes money by selling the Omnipod insulin delivery system through a recurring-use (“razor/razorblade”) model. The largest revenue driver is ongoing sales of disposable Pods that users replace regularly, creating repeat purchase demand tied to the active installed base. Insulet also generates revenue from sales of Omnipod controllers (depending on the system configuration and geography) and from commercialization of its platform through distribution channels. Reimbursement and access pathways are central to monetization: in the U.S., Pods are commonly reimbursed through pharmacy channels (and in some cases other payor pathways), while outside the U.S. the company sells through a mix of direct sales and third-party distributors, depending on the market. A significant factor supporting earnings is ecosystem compatibility—particularly integrations that enable automated insulin delivery when Omnipod is used with compatible continuous glucose monitoring (CGM) systems—because these features can improve adoption and retention; specific partner revenue terms are not publicly detailed in this prompt and are therefore null.

Insulet Financial Statement Overview

Summary

Strong multi-year revenue scaling to ~$2.7B (2025) with very high gross margin (~72%) and healthy EBITDA/operating margin expansion. Balance sheet appears significantly de-risked in 2025 with minimal debt and strong ROE, and cash flow is solid with positive FCF (~$378M). Offsetting factors include a 2025 step-down in net margin vs. 2024, weaker recent FCF momentum vs. 2024, OCF coverage below 1x, and a noted 2025 EBIT margin data inconsistency plus a one-year debt shift that should be validated.

Income Statement

Revenue has scaled strongly over the period (from ~$0.9B in 2020 to ~$2.7B in 2025) with solid recent growth in 2024 and still positive growth in 2025. Profitability improved meaningfully versus the low-profit years (2020–2022), and 2025 shows very strong gross margin (~72%) and a healthy EBITDA margin (~17%). The main weakness is earnings volatility: net margin peaked in 2024 (~20%) but fell materially in 2025 (~9%), and 2025 shows an EBIT margin data inconsistency (reported as 0% despite positive EBIT), which reduces confidence in margin trend interpretation for that year.

Balance Sheet

The balance sheet looks significantly stronger in 2025, with very low debt (~$18M) against a sizeable equity base (~$1.5B), implying minimal leverage and improved financial flexibility versus 2021–2024 when debt-to-equity was elevated (generally >1x and as high as ~3.0x in 2022). Returns on equity improved sharply from very low levels in 2020–2022 to strong levels in 2023–2025 (mid-teens to mid-30s). A key watch item is the dramatic drop in total debt from 2024 to 2025, which may reflect a major deleveraging event or classification change—investors should validate the sustainability and drivers of that shift.

Cash Flow

Cash generation improved substantially from earlier years, with operating cash flow rising to ~$569M in 2025 and free cash flow positive at ~$378M (a major turnaround versus negative free cash flow in 2020–2022). Cash conversion is generally supportive, with free cash flow running at roughly two-thirds to ~70% of net income in 2023–2025. The weakness is recent momentum: 2025 free cash flow declined versus 2024 (negative free cash flow growth), and operating cash flow has not fully covered reported earnings in recent years (coverage below 1x), suggesting working-capital or timing headwinds.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.71B	2.07B	1.70B	1.31B	1.10B
Gross Profit	1.94B	1.45B	1.16B	805.60M	752.10M
EBITDA	586.90M	423.70M	323.60M	109.00M	139.60M
Net Income	247.10M	418.30M	206.30M	4.60M	16.80M
Balance Sheet
Total Assets	3.19B	3.09B	2.59B	2.25B	2.05B
Cash, Cash Equivalents and Short-Term Investments	716.10M	953.40M	704.20M	674.70M	791.60M
Total Debt	1.05B	1.42B	1.45B	1.43B	1.29B
Total Liabilities	1.68B	1.88B	1.86B	1.77B	1.49B
Stockholders Equity	1.52B	1.21B	732.70M	476.40M	556.30M
Cash Flow
Free Cash Flow	377.70M	305.40M	70.10M	-38.30M	-190.80M
Operating Cash Flow	569.30M	430.30M	145.70M	119.00M	-68.10M
Investing Cash Flow	-222.70M	-146.20M	-119.40M	-191.10M	-82.70M
Financing Cash Flow	-595.30M	-28.10M	-13.60M	-40.30M	40.70M

Insulet Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 236.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PODD, the sentiment is Negative. The current price of 236.07 is below the 20-day moving average (MA) of 244.07, below the 50-day MA of 260.55, and below the 200-day MA of 300.03, indicating a bearish trend. The MACD of -6.12 indicates Negative momentum. The RSI at 37.33 is Neutral, neither overbought nor oversold. The STOCH value of 23.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PODD.

Insulet Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	77 Outperform	$25.12B	30.97	32.44%	―	14.21%	5.66%
STE	69 Neutral	$20.83B	32.31	10.21%	0.94%	5.15%	60.30%
PODD	68 Neutral	$16.62B	80.92	17.36%	―	27.12%	-41.72%
ZBH	65 Neutral	$18.12B	31.78	5.60%	1.05%	5.47%	-23.03%
PHG	64 Neutral	$26.95B	24.78	8.21%	3.30%	-0.76%	-55.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNDM	45 Neutral	$1.43B	-7.22	-141.98%	―	17.87%	-57.03%

Insulet Corporate Events

Insulet Issues Voluntary Omnipod 5 Device Correction

On March 12, 2026, Insulet initiated a voluntary medical device correction in the U.S. for specific lots of its Omnipod 5 Pods after product monitoring identified a manufacturing issue that can cause a tear in internal tubing and lead to under‑delivery of insulin. The company said only about 1.5% of its annual Omnipod 5 pod production is affected, all other Omnipod products remain safe to use, and it continues to manufacture and ship pods without anticipated disruption to product availability or new patient starts.

Insulet disclosed 18 reports of serious adverse events tied to high blood glucose levels, including hospitalizations and cases of diabetic ketoacidosis, but reported no deaths and noted that continuous glucose monitoring systems are not impacted. The company has updated its manufacturing processes and quality controls, expects to incur up to $40 million in related costs in 2026, will exclude these from adjusted results, and is maintaining its previously issued 2026 financial guidance, signaling limited expected impact on its operational outlook.

The most recent analyst rating on (PODD) stock is a Buy with a $338.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.

Insulet Finalizes Severance Terms for Departing CFO

On February 27, 2026, Insulet Corporation entered into a severance agreement with former Chief Financial Officer Ana M. Chadwick that aligns fully with previously disclosed executive compensation and severance arrangements. The agreement formalizes her post-termination benefits and incorporates standard provisions such as release of claims, mutual non-disparagement, and continued compliance with existing confidentiality, non-solicitation, non-compete, and intellectual property obligations, indicating no change to the company’s established executive severance framework or incremental financial impact.

The severance deal confirms that Ms. Chadwick’s departure terms remain consistent with Insulet’s Amended and Restated Executive Severance Plan and earlier filed disclosures, avoiding any new or enhanced payout commitments. This underscores management’s adherence to pre-set governance policies around executive transitions and suggests limited operational or financial disruption from the CFO’s exit for investors and other stakeholders.

The most recent analyst rating on (PODD) stock is a Buy with a $326.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.

Insulet Posts Strong Q4 Results, Expands Share Repurchase Program

Insulet reported strong fourth-quarter and full-year 2025 results on February 18, 2026, with revenue up about 31% for both periods and constant-currency growth of roughly 29% to 30%, marking a 10th straight year of at least 20% constant-currency revenue expansion. Growth was driven by the Omnipod franchise, particularly internationally, with higher gross margins, expanding operating margins, robust free cash flow, rising adjusted earnings, and record new customer starts that reinforced its leadership in automated insulin delivery systems.

The company’s board on February 13, 2026, approved a $350 million increase to its stock repurchase authorization, raising the total program to $475 million and leaving $415 million available as of February 16, with about $300 million earmarked for buybacks in the first quarter of 2026. Management framed the enlarged repurchase program and its 2026 guidance for low‑20% revenue growth and further adjusted margin expansion as signals of financial strength, capital discipline, and confidence in Insulet’s long-term competitive position and ability to deliver value to shareholders.

The most recent analyst rating on (PODD) stock is a Hold with a $274.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.

Insulet Extends Key Supply Agreement with NXP USA

On January 29, 2026, Insulet Corporation and NXP USA, Inc. entered into a 2026 Addendum, effective January 1, 2026, that extends the term of their existing 2017 purchase agreement and revises conditions related to pricing, product volume, and order flexibility. The amended arrangement is intended to secure continued supply and more adaptable commercial terms, which may enhance Insulet’s operational stability and cost management in its supply chain and could strengthen its positioning in securing critical components for its medical device production.

The most recent analyst rating on (PODD) stock is a Hold with a $280.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.

Insulet Revises Annual Incentive Plan for 2026

Insulet announced amendments to its Annual Incentive Plan effective January 1, 2026, with revisions that impact terms regarding termination, retirement eligibility for prorated awards, compensation recoupment, and award limits. These changes aim to refine operational clarity and position the company competitively in managing executive compensations, which may influence stakeholder trust and employee motivation.

The most recent analyst rating on (PODD) stock is a Buy with a $370.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.